Health Care/Hospital

"Momcozy Village" Campaign Elevates Support for Mothers with Upcoming Events and Initiatives

NEW YORK, May 7, 2024 /PRNewswire/ -- As we approach Mother's Day, Momcozy , a leader in maternal and infant care, is excited to share more details about its "Momcozy Village" campaign. This initiative focuses on stren...

2024-05-07 22:30 423

FDA Grants Orphan Drug Designation to 9MW2821

SHANGHAI, May 7, 2024 /PRNewswire/ -- Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced that its self-developed novel Nectin-4-targeting ADC (R&D code: 9MW2821) has been granted Orphan Drug Designation (ODD) by the U.S. Food and Drug Adminis...

2024-05-07 22:00 456

Meihua International Medical Technologies Co., Ltd. to Present at the Emerging Growth Conference on May 9, 2024

Meihua International Medical Technologies Co., Ltd. invites individual and institutional investors as well as advisors and analysts, to attend its real-time, interactive presentation at the Emerging Growth Conference. YANGZHOU, China, May 7, 2024 /PRNewswire/ -- Meihua International Medical Tech...

2024-05-07 21:08 568

Mr. Kong, Nano Labs' Chairman and CEO, Increased His Shareholding in the Company

HANGZHOU, China , May 7, 2024 /PRNewswire/ -- Nano Labs Ltd (Nasdaq: NA) ("we," the "Company" or "Nano Labs"), a leading fabless integrated circuit design company and product solution provider inChina, announced today that Mr. Jianping Kong, the Company's chairman and chief executive officer, inf...

2024-05-07 21:00 580

GC Genome to Present New Clinical Data on Colorectal Cancer Detection at the ASCO Annual Meeting 2024

YONGIN, South Korea, May 7, 2024 /PRNewswire/ -- GC Genome Corporation, a leading diagnostics company, today announced that it will present the new clinical data of its AI-based liquid biopsy platform on colorectal cancer detection at the 2024 American Society of Clinical Oncology (ASCO) Annual ...

2024-05-07 13:27 778

German car manufacturer visits HoneyNaps, a South Korean sleep tech company, to develop new automotive healthcare applications

Monitoring biosignals for both drivers and passengers - Analyzing and diagnosing with FDA-approved algorithm SEOUL, South Korea, May 6, 2024 /PRNewswire/ -- Amid the rapid advancement in automobile healthcare and digital healthcare markets, global car manufacturers are racing to adopt cutting ed...

2024-05-06 22:00 895

Datasea Pre-Announces Estimated Revenue of $12.5 Million for April 2024 Supporting its Prior Revenue Guidance of $86 Million for Fiscal 2024

DTSS on Track to Achieve Record Revenue for Fiscal 2024 as it Further Penetrates China's$528 Billion 5G Market BEIJING, May 6, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a digital technology company incorporated inNevada and engaged in innovative business seg...

2024-05-06 22:00 1219

HanAll Biopharma Announces Initiation of Phase III Randomized, Double-Masked Vehicle Controlled VELOS-4 Trial Evaluating Tanfanercept for Treatment of Dry Eye Disease

* HanAll has initiated a Phase III VELOS-4 study to evaluate the efficacy and safety of tanfanercept in dry eye based on the findings from the previous Phase III VELOS-3 study. * Tanfanercept demonstrated statistically significant improvement on the secondary outcome measure, Schirmer testing...

2024-05-03 19:00 1882

Zepp Health's Amazfit Unveils Bip 5 Unity: Elevating Health and Style Every Step of the Way

MILPITAS, Calif., May 2, 2024 /PRNewswire/ -- Zepp Health Corporation ("Zepp Health") (NYSE:ZEPP ), a global leader in smart...

2024-05-02 23:00 1216

Boryung Launches 2024 Humans In Space Challenge: Sending Experiments into Orbit

* Boryung to support the launch of space experiments into orbit for selected startups and researchers * Held for the third consecutive year, HIS presents an expanded ecosystem of engagements with NASA, ISS National Lab,MIT, and major space companies * Humans In Space(HIS) will serve as a glo...

2024-05-02 20:00 1092

Integrated cancer biotech Infinitopes secures £12.8m seed financing to enhance its Precision Immunomics™ antigen discovery technologies to target five more cancers

Funding also supports the start of phase I/IIa study for lead vaccine, ITOP1 OXFORD, England, May 2, 2024 /PRNewswire/ -- Infinitopes Precision Immunomics, an integrated cancer biotech combining world leading platforms in precision antigen discovery with vaccine vectors capable of durably stimula...

2024-05-02 07:01 1373

Shineco Develops Revolutionary New Product with Varied Applications to Positively Impact the Health Care Industry

BEIJING, May 1, 2024 /PRNewswire/ -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of technologically advanced healthcare products and services, announced today that its subsidiaries Fuzhou Medashan Biotechnology Co., Ltd. and Kaifeng Yixi Biotechnology Co., Ltd. have innov...

2024-05-01 17:14 1060

135th Canton Fair Showcases Leading Medical Devices, Elevating Global Health Management

GUANGZHOU, China, May 1, 2024 /PRNewswire/ -- In a significant move to meet the growing demand for health management solutions, the 135th China Import and Export Fair ("Canton Fair" or "the Fair") has brought together top-tier companies from theMedicines, Health Products and Medical Devices secto...

2024-05-01 13:40 1174

Jacobio Pharma Announced its KRAS G12C inhibitor reached the primary endpoint

BEIJING and SHANGHAI and BOSTON, April 30, 2024 /PRNewswire/ -- Jacobio Pharma (1167.HK) announced that the data from the Phase II registrational study of the KRAS G12C inhibitor glecirasib were offically reported at the April ASCO Plenary Series, which was held online. Prof. Yuankai Shi, chief ...

2024-05-01 08:59 1096

Eluminex Biosciences Announces FDA Acceptance of Investigational New Drug (IND) Application for EB-105 - A Novel Trispecific Fusion Antibody for Diabetic Macular Edema (DME) - and Upcoming Scientific Presentations

SAN FRANCISCO and SUZHOU, China, April 30, 2024 /PRNewswire/ -- Eluminex Biosciences (Eluminex), a privately-held biotechnology company focused on the development of advanced protein therapeutics for vision-threatening diseases and dermal facial aesthetics announced the acceptance of their EB-105...

2024-04-30 23:00 2021

Ambpomial Active Probiotic Yogurt Shines at the European Microbiome and Probiotics Forum, Demonstrating Its Innovative Strength to the World

THE HAGUE, Netherlands, April 30, 2024 /PRNewswire/ -- The 12th Microbiome and Probiotics R&D and Business Collaboration Forum was held with great fanfare in The Hague, Netherlands from April 23rd to 24th, 2024. This prestigious conference is a leading event in the probiotics sector, drawing toget...

2024-04-30 21:09 1021

National Medical Products Administration (NMPA) Approves Chipscreen Bioscience's Chidamide (Epidaza) combined with R-CHOP for the treatment of diffuse large B-cell lymphoma

SHENZHEN, China, April 30, 2024 /PRNewswire/ -- Shenzhen Chipscreen Biosciences Co., Ltd. (Chipscreen Biosciences, Stock Symbol: 688321.SH) announced that the company's lead innovative product Chidamide (Epidaza®) , an oral subtype-selective histone deacetylase (HDAC) inhibitor, combined with R-C...

2024-04-30 20:55 1234

A Potential First-In-Class Drug: CDE Approved Single-Arm Pivotal Clinical Study of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs

NANJING, China, April 30, 2024 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. (hereinafter referred to as "Leads Biolabs") announced that LBL-024, an anti-PD-L1/4-1BB bispecific antibody independently developed by Leads Biolabs with global intellectual property rights has received approval to co...

2024-04-30 20:16 1211

HanAll Biopharma Reports Q1 2024 Financial Results and Provides Business Update

* Delivered solid performance to start 2024, with record-breaking first quarter revenue of34.1 billion KRW. Strong sales momentum continued from key products, funding investments in ongoing R&D programs. * Phase 3 VELOS-4 study of tanfanercept in dry eye disease expected to be initiated in th...

2024-04-30 19:00 963

I-MAB Filed 2023 Annual Report on Form 20-F

ROCKVILLE, Md., April 30, 2024 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a U.S.-based, global biotech company, exclusively focused on the development and potential commercialization of highly differentiated immunotherapies for the treatment of cancer, today announced that it has filed...

2024-04-30 19:00 2411
12345 ... 255